The majority of these patients were FGFR3-TACC3 positive, but we also observed 1 case of a FGFR2-INA fusion that was originally described in gliomas, and 2 novel FGFR fusions, including SLC20A2-FGFR1 and FGFR4-GAPGEFL1. This evidence concerns the gene SLC20A2 and central nervous system cancer.